Closing Remarks

October 27, 2020

Sudhir Sivakumaran, Executive Director, CPAD
The Journey Continues...

• Integrating data from multiple sources into a standardized and centralized repository is the solid foundation upon which we can generate novel quantitative and analytical tools and solutions

• Effective and efficient clinical trial design with better patient stratification, and use of established and validated efficacy endpoints

• Accounting for and promoting diversity in future clinical trials

• Better understanding of what matters most to patients and what are the most clinically meaningful measures for tracking disease progression and treatment efficacy
Thank you!

Pharmaceutical Industry

- AbbVie Inc.
- Biogen
- Boehringer Ingelheim Pharmaceuticals Inc.
- Eisai
- Eli Lilly and Company
- F. Hoffman La Roche
- IXICO plc.
- Janssen Research & Development LLC
- Merck, Sharp & Dohme Corporation
- Novartis Pharmaceuticals Corporation
- Oxford Brain Diagnostics
- Takeda Pharmaceuticals
- Unlearn.AI, Inc
- vTv Therapeutics

Government and Regulatory Agencies

- European Medicines Agency (EMA)
- National Institute on Aging (NIA)
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- U.S. Food and Drug Administration (FDA)

Non-profit research Organizations

- Alzheimer’s Association
- Alzheimer’s Drug Discovery Foundation
- Alzheimer’s Research UK
- CHDI Foundation
- UsAgainstAlzheimer’s

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 62% funded by FDA/HHS, totaling $14,448,917, and 38% percent funded by non-government source(s), totaling $8,669,646. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
CPAD Team

- Sudhir Sivakumaran, Executive Director, CPAD
- Nathan Hanan, Scientific Director of Pharmacometrics, Quantitative Medicine
- Klaus Romero, CSO, C-Path
- Jackson Burton, Executive Director, Quantitative Medicine
- Yashmin Karten, Sr. Project Manager, CPAD
- Eileen Priest, Project Coordinator, CPAD
- Zihan Cui, Developer, Quantitative Medicine
- Hazel White, Intern, CPAD
- Vanda Molnar, Data Manager, CPAD
- Bob Stafford, Sr. Data Specialist, Data Programming Team Lead, Data Collaboration Center
- Jagdeep Podichetty, Scientific Director, Quantitative Medicine
- Maedeh Beheshti, Postdoctoral Fellow, Artificial Intelligence (AI)
- Joseph Scheeren, President & CEO, C-Path